Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L MacMillan

Showing results (551-560 of 574) with videos related to

Pageof 58
Sort By:
Journal for Immunotherapy of Cancer|July 24, 2025
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancerMelissa J Khaw, Nicholas A Zorko, Philippa R Kennedy, et al.
Transplantation and Cellular Therapy|July 21, 2022
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.
Transplantation and Cellular Therapy|December 30, 2025
Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults with Acute Myeloid Leukemia: A CIBMTR ReportHemalatha G Rangarajan, Deepakbabu Chellapandian, Rasha Atshan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 29, 2017
Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research ReportPooja Khandelwal, Heather R Millard, Elizabeth Thiel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2013
Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemiaMouhab Ayas, Wael Saber, Stella M Davies, et al.
Haematologica|December 30, 2020
Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemiaAnna Hecht, Julia A Meyer, Astrid Behnert, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 26, 2016
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell TransplantationKaren Ballen, Kwang Woo Ahn, Min Chen, et al.
Blood Advances|August 9, 2018
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802Shernan G Holtan, Todd E DeFor, Angela Panoskaltsis-Mortari, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Pageof 58

Showing results (551-560 of 574) with videos related to

Sort By:
Pageof 58
Journal for Immunotherapy of Cancer|July 24, 2025
Novel trispecific killer engager targeting B7-H3 enhances natural killer cell antitumor activity against head and neck cancerMelissa J Khaw, Nicholas A Zorko, Philippa R Kennedy, et al.
Transplantation and Cellular Therapy|July 21, 2022
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic MalignancyCatherine J Lee, Tao Wang, Karen Chen, et al.
Transplantation and Cellular Therapy|December 30, 2025
Impact of Extramedullary Disease at Diagnosis on Outcomes Post Allogeneic Hematopoietic Cell Transplant in Children and Young Adults with Acute Myeloid Leukemia: A CIBMTR ReportHemalatha G Rangarajan, Deepakbabu Chellapandian, Rasha Atshan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 29, 2017
Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research ReportPooja Khandelwal, Heather R Millard, Elizabeth Thiel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2013
Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemiaMouhab Ayas, Wael Saber, Stella M Davies, et al.
Haematologica|December 30, 2020
Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemiaAnna Hecht, Julia A Meyer, Astrid Behnert, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 26, 2016
Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell TransplantationKaren Ballen, Kwang Woo Ahn, Min Chen, et al.
Blood Advances|August 9, 2018
Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802Shernan G Holtan, Todd E DeFor, Angela Panoskaltsis-Mortari, et al.
The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.
Pageof 58